Halozyme Therapeutics Inc. HALO

NAS: HALO | ISIN: US40637H1095   30/04/2025
61,42 USD (+0,99%)
(+0,99%)   30/04/2025

28 april 2025 · Halozyme to Report First Quarter 2025 Financial and Operating Results · Persbericht

28 april 2025 · Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Persbericht

24 april 2025 · Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation · Persbericht

11 april 2025 · Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy · Persbericht

9 april 2025 · European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility · Persbericht

7 april 2025 · European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer · Persbericht

31 maart 2025 · Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications · Persbericht

13 september 2024 · Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer · Persbericht

28 augustus 2024 · Halozyme to Present at Upcoming Investor Conferences · Persbericht

6 augustus 2024 · Halozyme Reports Second Quarter 2024 Financial And Operating Results · Persbericht

23 juli 2024 · Halozyme to Report Second Quarter 2024 Financial and Operating Results · Persbericht

25 juni 2024 · Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis · Persbericht

21 juni 2024 · Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy · Persbericht

6 juni 2024 · Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook · Persbericht

5 juni 2024 · Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform · Persbericht

4 juni 2024 · Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference · Persbericht

21 mei 2024 · Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE® · Persbericht

8 mei 2024 · Halozyme to Participate in Upcoming Investor Conferences · Persbericht

7 mei 2024 · Halozyme Reports First Quarter 2024 Financial And Operating Results · Persbericht

25 april 2024 · Mahesh Krishnan Elected to Halozyme's Board of Directors · Persbericht

Mijn selecties